Pulmonxcorp Stock Cash And Equivalents
| LUNG Stock | USD 9.82 0.44 4.69% |
PulmonxCorp fundamentals help investors to digest information that contributes to PulmonxCorp's financial success or failures. It also enables traders to predict the movement of PulmonxCorp Stock. The fundamental analysis module provides a way to measure PulmonxCorp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PulmonxCorp stock.
PulmonxCorp | Cash And Equivalents |
PulmonxCorp Company Cash And Equivalents Analysis
PulmonxCorp's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current PulmonxCorp Cash And Equivalents | 162.09 M |
Most of PulmonxCorp's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PulmonxCorp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
PulmonxCorp Cash And Equivalents Driver Correlations
Understanding the fundamental principles of building solid financial models for PulmonxCorp is extremely important. It helps to project a fair market value of PulmonxCorp Stock properly, considering its historical fundamentals such as Cash And Equivalents. Since PulmonxCorp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of PulmonxCorp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of PulmonxCorp's interrelated accounts and indicators.
Click cells to compare fundamentals
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
PulmonxCorp Cash And Cash Equivalents Changes
Cash And Cash Equivalents Changes |
|
In accordance with the recently published financial statements, PulmonxCorp has 162.09 M in Cash And Equivalents. This is 80.25% lower than that of the Health Care Equipment & Supplies sector and 70.95% lower than that of the Health Care industry. The cash and equivalents for all United States stocks is 94.0% higher than that of the company.
PulmonxCorp Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PulmonxCorp's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PulmonxCorp could also be used in its relative valuation, which is a method of valuing PulmonxCorp by comparing valuation metrics of similar companies.PulmonxCorp is currently under evaluation in cash and equivalents category among related companies.
PulmonxCorp Current Valuation Drivers
We derive many important indicators used in calculating different scores of PulmonxCorp from analyzing PulmonxCorp's financial statements. These drivers represent accounts that assess PulmonxCorp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of PulmonxCorp's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.4B | 2.5B | 1.2B | 312.7M | 484.2M | 460.0M | |
| Enterprise Value | 1.4B | 2.3B | 1.0B | 235.4M | 441.8M | 419.7M |
PulmonxCorp Fundamentals
| Return On Equity | -0.46 | ||||
| Return On Asset | -0.21 | ||||
| Profit Margin | (0.80) % | ||||
| Operating Margin | (0.77) % | ||||
| Current Valuation | 303.85 M | ||||
| Shares Outstanding | 38.81 M | ||||
| Shares Owned By Insiders | 4.67 % | ||||
| Shares Owned By Institutions | 92.80 % | ||||
| Number Of Shares Shorted | 1.73 M | ||||
| Price To Book | 2.59 X | ||||
| Price To Sales | 4.46 X | ||||
| Revenue | 68.67 M | ||||
| Gross Profit | 39.87 M | ||||
| EBITDA | (59.99 M) | ||||
| Net Income | (60.84 M) | ||||
| Cash And Equivalents | 162.09 M | ||||
| Cash Per Share | 4.35 X | ||||
| Total Debt | 41.42 M | ||||
| Debt To Equity | 0.15 % | ||||
| Current Ratio | 9.43 X | ||||
| Book Value Per Share | 2.86 X | ||||
| Cash Flow From Operations | (37.61 M) | ||||
| Short Ratio | 2.57 X | ||||
| Earnings Per Share | (1.60) X | ||||
| Price To Earnings To Growth | (0.42) X | ||||
| Target Price | 15.4 | ||||
| Number Of Employees | 279 | ||||
| Beta | 0.6 | ||||
| Market Capitalization | 381.13 M | ||||
| Total Asset | 178.95 M | ||||
| Retained Earnings | (411.16 M) | ||||
| Working Capital | 127.27 M | ||||
| Net Asset | 178.95 M |
About PulmonxCorp Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PulmonxCorp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PulmonxCorp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PulmonxCorp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards PulmonxCorp in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, PulmonxCorp's short interest history, or implied volatility extrapolated from PulmonxCorp options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out PulmonxCorp Piotroski F Score and PulmonxCorp Altman Z Score analysis. For more detail on how to invest in PulmonxCorp Stock please use our How to Invest in PulmonxCorp guide.You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Complementary Tools for PulmonxCorp Stock analysis
When running PulmonxCorp's price analysis, check to measure PulmonxCorp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PulmonxCorp is operating at the current time. Most of PulmonxCorp's value examination focuses on studying past and present price action to predict the probability of PulmonxCorp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PulmonxCorp's price. Additionally, you may evaluate how the addition of PulmonxCorp to your portfolios can decrease your overall portfolio volatility.
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data |
Is PulmonxCorp's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PulmonxCorp. If investors know PulmonxCorp will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PulmonxCorp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.60) | Revenue Per Share 1.909 | Quarterly Revenue Growth 0.297 | Return On Assets (0.21) | Return On Equity (0.46) |
The market value of PulmonxCorp is measured differently than its book value, which is the value of PulmonxCorp that is recorded on the company's balance sheet. Investors also form their own opinion of PulmonxCorp's value that differs from its market value or its book value, called intrinsic value, which is PulmonxCorp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PulmonxCorp's market value can be influenced by many factors that don't directly affect PulmonxCorp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PulmonxCorp's value and its price as these two are different measures arrived at by different means. Investors typically determine if PulmonxCorp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PulmonxCorp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.